|
Number of patients
|
271
|
425
| |
|
Recipient age at SCT (years, range)
|
53 (18–76)
|
38 (18–74)
|
<10−4
|
|
Recipient age (by classes), n (%)
| | |
<0.0001
|
|
< 30
|
46 (17.0 %)
|
148 (34.8 %)
| |
|
30–40
|
32 (11.8 %)
|
82 (19.3 %)
| |
|
40–50
|
45 (16.6 %)
|
98 (23.1 %)
| |
|
≥ 50
|
148 (54.6 %)
|
97 (22.8 %)
| |
|
Recipient gender, n (%)
| | |
0.42
|
|
Male
|
153 (56.5 %)
|
252 (59.6 %)
| |
|
Female
|
118 (43.5 %)
|
171 (40.4 %)
| |
|
Year of SCT (median), year (%)
|
2010
|
2011
|
0.65
|
|
2001–2007
|
23 (8.5 %)
|
74 (17.4 %)
|
<0.0001
|
|
2008–2012
|
248 (91.5 %)
|
351 (82.6 %)
|
|
Interval from diagnosis to SCT (days, range)
|
299 (52–3892)
|
272 (41–3689)
|
0.24
|
|
Donor age
|
37 years (19–71)
|
42 years (12–70)
|
0.83
|
|
Donor age (by classes), year (%)
| | |
0.55
|
|
< 30
|
39 (29.3 %)
|
54 (29.2 %)
| |
|
30–40
|
32 (24.1 %)
|
33 (17.8 %)
| |
|
40–50
|
29 (21.8 %)
|
46 (24.9 %)
| |
|
≥ 50
|
33 (24.8 %)
|
52 (28.1 %)
| |
|
Donor gender, n (%)
| | |
0.69
|
|
Male
|
138 (50.9 %)
|
223 (52.5 %)
| |
|
Female
|
133 (49.1 %)
|
202 (47.5 %)
| |
|
Female donor to male recipient, n (%)
|
76 (28 %)
|
119 (28.1 %)
|
0.98
|
|
Diagnosis, n (%)
| | |
<0.0001
|
|
AML
|
217 (80.1 %)
|
286 (67.3 %)
| |
|
Good cytogenetics
|
8 (6 %)
|
19 (14 %)
|
|
Intermediate cytogenetics
|
47 (37 %)
|
53 (39 %)
| |
|
Poor cytogenetics
|
19 (15 %)
|
18 (13 %)
| |
|
Secondary AML
|
54 (42 %)
|
45 (33 %)
| |
|
Missing cytogenetics
|
89 (41 %)
|
151 (53 %)
| |
|
ALL
|
54 (19.9 %)
|
139 (32.7 %)
|
|
Phi+ ALL
|
15 (54 %)
|
27 (36 %)
|
|
Missing cytogenetics
|
26 (48 %)
|
64 (46 %)
| |
|
Disease status at SCT, n (%)
| | |
<0.0001
|
|
CR1
|
78 (28.8 %)
|
175 (41.2 %)
| |
|
≥ CR2
|
67 (24.7 %)
|
118 (27.8 %)
| |
|
Active disease
|
126 (46.5 %)
|
132 (31.1 %)
| |
|
Karnosky at SCT, n (%)
| | |
0.05
|
|
≤ 80 %
|
101 (39.9 %)
|
109 (32 %)
| |
|
> 80 %
|
152 (60.1 %)
|
232 (68 %)
| |
|
Missing
|
18 (6.7 %)
|
84 (19.8 %)
| |
|
Patient positive CMV serology, n (%)
|
213 (79.8 %)
|
311 (78.3 %)
|
0.66
|
|
CMV risk, n (%)
| | |
0.06
|
|
Low
|
35 (13.3 %)
|
59 (15.2 %)
| |
|
Intermediate
|
169 (64.2 %)
|
272 (69.3 %)
| |
|
High
|
59 (22.4 %)
|
56 (14.5 %)
| |
